A new review details the major updates to the ACR's Lung-RADS system, from Category 0 and expanded juxtapleural criteria to ...
Nashville advocates say increasing lung cancer screening and awareness could catch the disease earlier, when patients have ...
Discover CHEST 2026 findings on CT phenotyping, TAPSE/sPAP risk scores, artesunate, telomere length and inhaled nintedanib in ...
In patients with extensive-stage small cell lung cancer (ES-SCLC), tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more ...
The investigational KRAS G12C inhibitor prolongs overall survival in previously treated advanced lung cancer vs existing ...
Women make up more than half the population, and their heart health must be a part of everyday care across medicine,’ said Dr ...
As I looked down at my patient, explaining that the factories likely had contributed to her sickness, I felt a renewed determination to fight. To work to heal not only my patient, but the system that ...
Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly longer and ...
The drop in smoking rates in the United States and other countries has unexpectedly shed light on this as an emerging health issue ...
Bristol Myers Squibb reported that one patient died after receiving its investigational CAR-T therapy in an early autoimmune trial ...
Genentech's divarasib beat sotorasib and adagrasib on PFS and OS in a Phase III NSCLC trial. Read the full results and what they mean for KRAS G12C treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results